An HKBU delegation displayed an impressive array of about 20 biotechnology inventions produced by HKBU scholars and also explored partnership or licensing opportunities during the BIO International Convention held from 19 to 22 June at San Diego, USA.
The HKBU inventions included personalised neural stem cells technology for treatment of neurodegenerative diseases, a chemical tool that monitors cells causing cancers and genetic diseases, a Chinese medicinal formulation for treatment of inflammatory bowel disease, novel anti-cancer drugs, and an innovative laboratory device.
The HKBU team was among nine exhibitors in the Hong Kong pavilion at the Convention, showcasing their products and services in biopharmaceuticals, industrial biotechnology, life science trade, medical devices and diagnostics. They were among 16,000 representatives from more than 5,000 exhibitors in 70 countries and regions at the Convention. Representatives of top pharmaceutical companies and research centres visited the HKBU booth including from Intelligent Pharma, JT Pharma, the Cedars Sinar Medical Center, Mitsubishi Tanabe Pharma, GE Healthcare, AbbVie Inc and Sanofi.
The HKBU team also visited The Genomics Institute of the Novartis Research Foundation, the Scripps Research Institute, Crown Bioscience Inc and Johnson & Johnson Innovation - JLABs San Diego. Team members learnt about the premier platforms for facilitating new drug development programmes, and a capital efficient and flexible platform to enhance commercialisation of products.
The HKBU team comprised Associate Head of the Department of Biology Professor Ken Yung, Associate Professor of the Teaching and Research Division of the School of Chinese Medicine Dr Zhang Hongjie, the Head of Knowledge Transfer Office Dr Alfred Tan and Intellectual Property Licensing Manager Ms Mandy Liu.